Brief: Cytokinetics Q4 Basic EPS USD -1.5
Feb 24 (Reuters) - Cytokinetics Q4 R&D revenue USD 2.755 million. Q4 net income USD -183.031 million Q4 operating income USD -178.366 million Q4 operating expenses USD 196.121 million
Recent news on Cytokinetics, Incorporated
See all newsBrief: Cytokinetics To Announce Third Quarter Results On November 4, 2026
Brief: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Cytokinetics Announces Additional Data From Acacia-Hcm Presented At The Hfsa Annual Scientific Meeting 2026
Brief: Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy
U.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech